Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Swiss drug maker Roche agreed Thursday to buy the 44 percent of biotech company Genentech it doesn't already own for $46.8 billion in cash, ending a sometimes…
Roche and Genentech today announced that they have entered into a merger agreement under which Roche will acquire the outstanding shares of Genentech that it…
Roche Holding completed a $46.8 billion acquisition of biotech firm Genentech in 2009, culminating over two decades of partnership and prioritizing…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Roche acquired the 44% of Genentech it did not already own for $46.8 billion ($95 per share), making Genentech a wholly-owned subsidiary. The deal gave Roche full control of Genentech's blockbuster oncology portfolio including Avastin, Herceptin, and Rituxan, and its world-leading biologics R&D platform.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Genentech, Inc. (Roche Group) (this deal) | 2009 | $46.8B | 72 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2009 deals · Roche Holding AG deals · Immunology deals